Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging–Proton Density Fat Fraction

Santos Carvajal-Gonzalez , Theresa Tuthill , Vincent Wai-Sun Wong , Amy Lauren Ashworth , Zeid Kayali , Céline Fournier-Poizat , Neeta B. Amin
{"title":"Modeling Reductions in Liver Fat: Comparing Noninvasive Tests to Magnetic Resonance Imaging–Proton Density Fat Fraction","authors":"Santos Carvajal-Gonzalez ,&nbsp;Theresa Tuthill ,&nbsp;Vincent Wai-Sun Wong ,&nbsp;Amy Lauren Ashworth ,&nbsp;Zeid Kayali ,&nbsp;Céline Fournier-Poizat ,&nbsp;Neeta B. Amin","doi":"10.1016/j.gastha.2025.100669","DOIUrl":null,"url":null,"abstract":"<div><h3>Background and Aims</h3><div>Magnetic resonance imaging–proton density fat fraction (MRI-PDFF) is an accurate, noninvasive tool for diagnosing metabolic dysfunction–associated steatotic liver disease, but its feasibility is limited in routine clinical practice. We aimed to assess the clinical utility of alternative, cost-efficient approaches for assessing liver fat changes and their relationship with MRI-PDFF changes.</div></div><div><h3>Methods</h3><div>This is a secondary analysis of a phase 2a study that included adults with metabolic dysfunction–associated steatotic liver disease who received clesacostat, a selective, reversible inhibitor of acetyl-CoA carboxylase. In this secondary analysis, responders were defined as those in whom a ≥30% decrease in liver fat by MRI-PDFF was observed with clesacostat or placebo. Other endpoints were evaluated for their ability to predict MRI-PDFF responder status, including controlled attenuation parameter (CAP), liver enzymes (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase), metabolic dysfunction–associated steatohepatitis–related biomarkers (liver stiffness measurement by vibration-controlled transient elastography, cytokeratin 18-M30, and cytokeratin 18-M65), and markers of hepatic steatosis (hepatic steatosis index and fatty liver index). These relationships were investigated through correlation, univariate, and multivariable regression analyses.</div></div><div><h3>Results</h3><div>Of 260 participants with a baseline and on-treatment measure at week 12 or week 16, 143 were responders. Based on correlation analyses, a significant but weak positive correlation between MRI-PDFF and CAP measurements of relative percentage change from baseline in liver fat was observed. By combining the selected 6 parameters (CAP, hepatic steatosis index, fatty liver index, alanine aminotransferase, gamma-glutamyl transferase, and cytokeratin 18-M65) through multivariable regression modeling, responders can be predicted with a high level of sensitivity and specificity (mean area under the receiver operating characteristic curve = 0.831 from 10-fold cross-validation).</div></div><div><h3>Conclusion</h3><div>Modeling multiple noninvasive assessments of liver fat closely aligned with MRI-PDFF measurements. These data support further assessment of its suitability in real-world clinical practice.</div></div>","PeriodicalId":73130,"journal":{"name":"Gastro hep advances","volume":"4 7","pages":"Article 100669"},"PeriodicalIF":0.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gastro hep advances","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2772572325000561","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background and Aims

Magnetic resonance imaging–proton density fat fraction (MRI-PDFF) is an accurate, noninvasive tool for diagnosing metabolic dysfunction–associated steatotic liver disease, but its feasibility is limited in routine clinical practice. We aimed to assess the clinical utility of alternative, cost-efficient approaches for assessing liver fat changes and their relationship with MRI-PDFF changes.

Methods

This is a secondary analysis of a phase 2a study that included adults with metabolic dysfunction–associated steatotic liver disease who received clesacostat, a selective, reversible inhibitor of acetyl-CoA carboxylase. In this secondary analysis, responders were defined as those in whom a ≥30% decrease in liver fat by MRI-PDFF was observed with clesacostat or placebo. Other endpoints were evaluated for their ability to predict MRI-PDFF responder status, including controlled attenuation parameter (CAP), liver enzymes (alanine aminotransferase, aspartate aminotransferase, and gamma-glutamyl transferase), metabolic dysfunction–associated steatohepatitis–related biomarkers (liver stiffness measurement by vibration-controlled transient elastography, cytokeratin 18-M30, and cytokeratin 18-M65), and markers of hepatic steatosis (hepatic steatosis index and fatty liver index). These relationships were investigated through correlation, univariate, and multivariable regression analyses.

Results

Of 260 participants with a baseline and on-treatment measure at week 12 or week 16, 143 were responders. Based on correlation analyses, a significant but weak positive correlation between MRI-PDFF and CAP measurements of relative percentage change from baseline in liver fat was observed. By combining the selected 6 parameters (CAP, hepatic steatosis index, fatty liver index, alanine aminotransferase, gamma-glutamyl transferase, and cytokeratin 18-M65) through multivariable regression modeling, responders can be predicted with a high level of sensitivity and specificity (mean area under the receiver operating characteristic curve = 0.831 from 10-fold cross-validation).

Conclusion

Modeling multiple noninvasive assessments of liver fat closely aligned with MRI-PDFF measurements. These data support further assessment of its suitability in real-world clinical practice.
模拟肝脏脂肪减少:比较无创测试和磁共振成像质子密度脂肪分数
背景与目的磁共振成像-质子密度脂肪分数(MRI-PDFF)是一种准确、无创的诊断代谢功能障碍相关脂肪变性肝病的工具,但其在常规临床实践中的可行性有限。我们的目的是评估评估肝脏脂肪变化及其与MRI-PDFF变化的关系的替代、成本效益方法的临床效用。方法:这是一项2a期研究的二级分析,该研究包括患有代谢功能障碍相关脂肪变性肝病的成年人,他们接受了选择性、可逆的乙酰辅酶a羧化酶抑制剂clesacostat。在这一次要分析中,应答者被定义为那些使用塞司他或安慰剂通过MRI-PDFF观察到肝脂肪减少≥30%的人。其他终点评估了它们预测MRI-PDFF应答状态的能力,包括控制衰减参数(CAP)、肝酶(丙氨酸转氨酶、天冬氨酸转氨酶和γ -谷氨酰转移酶)、代谢功能障碍相关的脂肪性肝炎相关生物标志物(通过振动控制的瞬时弹性成像、细胞角蛋白18-M30和细胞角蛋白18-M65测量肝脏硬度)、肝脂肪变性指标(肝脂肪变性指数、脂肪肝指数)。通过相关、单变量和多变量回归分析来研究这些关系。结果在第12周或第16周接受基线和治疗测量的260名参与者中,143名有反应。基于相关分析,观察到MRI-PDFF和CAP测量的肝脂肪相对基线变化百分比之间存在显著但微弱的正相关。将选择的6个参数(CAP、肝脂肪变性指数、脂肪肝指数、丙氨酸转氨酶、γ -谷氨酰转移酶、细胞角蛋白18-M65)通过多变量回归建模,预测应答者具有较高的敏感性和特异性(10倍交叉验证,应答者工作特征曲线下平均面积= 0.831)。结论:肝脏脂肪的多种无创评估模型与MRI-PDFF测量结果密切相关。这些数据支持进一步评估其在现实世界临床实践中的适用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Gastro hep advances
Gastro hep advances Gastroenterology
CiteScore
0.80
自引率
0.00%
发文量
0
审稿时长
64 days
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信